卵巢癌新辅助化疗患者静脉血栓栓塞风险研究
该研究基于单中心卵巢癌数据库,纳入2015年4月至2018年9月接受新辅助化疗的卵巢癌患者290例,评估静脉血栓栓塞(VTE)发生率及临床危险因素。结果显示总体VTE发生率为25.9%(75例),其中13.8%在初始化疗前即存在VTE,11.6%在新辅助化疗期间发生;FIGO IV期是新生VTE的唯一危险因素(OR 3.9,95%CI 1.2-13.6,p=0.03)。
要点
- 接受新辅助化疗的晚期卵巢癌患者VTE总体发生率达25.9%。
- 13.8%的患者在开始新辅助化疗前即已存在VTE。
- FIGO IV期是新生VTE的唯一独立危险因素(OR 3.9)。
核心结论
- 接受新辅助化疗的晚期卵巢癌患者发生血栓栓塞事件的风险极高,可发生在初诊时或诱导化疗期间。
- FIGO IV期疾病是新生VTE的唯一相关危险因素。
研究设计与样本
- 回顾性队列研究,利用单中心卵巢癌数据库,纳入2015年4月至2018年9月接受新辅助化疗的卵巢癌患者290例。
- VTE事件包括临床诊断的深静脉血栓和/或肺栓塞,按治疗阶段分类统计。
主要发现
- 总体VTE发生率为25.9%(75/290)。
- 11.6%(27例)在新辅助化疗期间(IDS前)发生VTE。
- 3.9%(6例)在术中至IDS后28天内发生VTE;1.3%(2例)在辅助化疗期间发生VTE。
- FIGO IV期与新生VTE风险增加相关(OR 3.9,95%CI 1.2-13.6,p=0.03)。
关键数值与推荐
- VTE事件按治疗阶段定义:P0为初诊/新辅助化疗前;P1为新辅助化疗期间至IDS前;P2为术中至IDS后28天;P3为辅助化疗期间。
- 新生VTE的危险因素分析显示仅FIGO IV期有统计学意义(OR 3.9,95%CI 1.2-13.6,p=0.03)。
临床怎么用
- 对新辅助化疗的卵巢癌患者,尤其FIGO IV期,应考虑加强VTE筛查或预防性抗凝。
- Khorana评分在该人群中不具有预测价值,不应依赖其决定是否抗凝。
局限性
- 回顾性单中心研究,样本量有限。
- 未报告Khorana评分预测价值的具体数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the incidence of venous thromboembolism (VTE) and define clinical risk factors associated with the development of new-onset VTE in patients receiving neoadjuvant chemotherapy (NACT) for ovarian cancer (OC). METHODS: An institutional ovarian cancer database was used to identify all OC patients receiving NACT from 04/2015-09/2018. VTE events were recorded and included clinically diagnosed deep venous thrombosis (DVT) and/or pulmonary embolism (PE). The incidence of VTE events was categorized according to treatment phases (P): P0) First visit/prior to induction of NACT; P1) during NACT before interval debulking surgery (IDS); P2) intraoperative through day 28 post-IDS; P3) during adjuvant chemotherapy. RESULTS: A total of 290 patients were identified during the study period. Seventy-five (25.9%) developed a VTE at some point from time of presentation through the peri-operative period. Forty (13.8%) presented with VTE prior to initiation of NACT. An additional 27 (11.6%) developed a VTE during NACT (P1); 6 (3.9%) during the intraoperative and 28-day post-operative period (P2); and 2 (1.3%) during the adjuvant period (P3). The overall VTE rate was 25.9% (n = 75). FIGO stage IV disease was the only factor associated with increased risk for a new-onset VTE [Odds Ratio (OR): 3.9 (95% Confidence Interval [CI] = 1.2-13.6; p = 0.03]. CONCLUSIONS: Patients receiving NACT for advanced OC are at extremely high risk for developing thromboembolic events, either at initial presentation or during induction of NACT, a treatment phase that is traditionally without use of prophylactic anticoagulation. Since Khorana scoring is not predictive in this population, clinicians might need to consider increased screening or use of prophylactic anticoagulation in patients receiving NACT for OC, particularly in advanced metastatic disease.
引用
- Basaran D, Boerner T, Suhner J, et al. Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. Gynecol Oncol. 2021. PMID: 34312001. doi:10.1016/j.ygyno.2021.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。